Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Bead-Based Capture Kit Eases Enrichment and Cleanup of DNA Libraries

By BiotechDaily International staff writers
Posted on 13 Jun 2013
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
A newly released bead-based capture system was designed to provide genomic researchers with a sensitive and robust method for capture and purification of DNA sample libraries enabling high-quality targeted sequencing results.

NimbleGen (Madison, WI, USA), the genomics products subsidiary of Roche (Basel, Switzerland), recently announced the global launch of its SeqCap EZ Pure Capture Bead Kit.

This kit offers researchers a set of capture and purification beads used to prevent secondary capture and isolate DNA sample libraries from contaminants during amplification. It, therefore, represents a sensitive and robust method for cleanup of DNA sample libraries for high-quality DNA sequencing results


The kit includes SeqCap EZ Capture Beads and SeqCap EZ Purification Beads. Capture beads are used to recover the captured DNA sample from the hybridization of the DNA sample library and the SeqCap EZ Library. Purification beads are used to purify the amplified DNA sample library and the amplified capture DNA sample library after LM-PCR (ligase mediated - polymerase chain reaction). Roche provides a comprehensive set of reagents and probe pools for superior target enrichment performance. The probe pools include exome libraries, gene panels, and custom designs.

In addition to the SeqCap EZ Capture Beads Kit, Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.


Related Links:

NimbleGen
Roche


Channels

Genomics/Proteomics

view channel
Image: Nomarski interference contrast photomicrographs of Cryptosporidium in the feces of an HIV-positive human (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).

Advanced Genetic Tools Revamp Search for Drugs to Treat Cryptosporidium

Genetically engineered modifications to genome of the diarrhea-causing parasite Cryptosporidium are expected to expedite research towards vaccine and drug development to prevent or cure infection by this pathogen.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.